Sector News

Shire to split operations in two

January 16, 2018
Life sciences

Shire has unveiled plans to split its operations into two separate entities – a neuroscience division and rare diseases one, and will later decide whether they should be listed independently.

The proposal follows the first stage of a strategic review of the firm’s neuroscience business, which concluded that it “warrants additional focus and investment”.

According to the Dublin, Ireland-headquartered group, the move will see each division benefit from “a sharper management focus, greater strategic clarity, and an increased ability to deploy resources to key growth priorities”.

Operational performance metrics of each division should be reported separately from the first quarter of this year.

Meanwhile, the second stage of the review will further evaluate all strategic alternatives, including the merits of an independent listing for each of the two divisions.

“Our new Rare Disease and Neuroscience Divisions will be well positioned for growth, profitability, innovation, and serving the needs of patients,” said Shire chief executive Flemming Ornskov.

The firm also said it has a promising late stage pipeline with fifteen programs currently in Phase III, and that it expects total revenues to reach $17-18 billion by 2020.

By Selina McKee

Source: Pharma Times

comments closed

Related News

January 19, 2025

AI set to revolutionise pharmaceutical R&D says GlobalData

Life sciences

AI is poised to significantly lower pharmaceutical R&D costs through efficient drug discovery, optimised clinical trials, and predictive data analysis, according to a GlobalData survey. The leading data and analytics company’s report, “The State of the Biopharmaceutical Industry – 2025,” highlights AI’s potential to boost productivity and cut costs in the coming year.

January 19, 2025

Gilead and LEO Pharma partner to develop oral STAT6 program

Life sciences

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory diseases such as atopic dermatitis, asthma, and COPD.

January 19, 2025

JPM25: Medtronic begins rolling out adaptive brain stimulation for Parkinson’s after EU approval

Life sciences

While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now received a European approval for what it describes as the first closed-loop therapy approach—allowing for self-adjusting neuromodulation in real time to help control the condition’s motor symptoms.

How can we help you?

We're easy to reach